Moderna, Inc. (NASDAQ:MRNA) Barclays 26th Annual Global Healthcare Conference Call March 12, 2024 2:35 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head, Investor Relations Conference Call Participants Gena Wang - Barclays Gena Wang Welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover SMID cap biotech. It is my great pleasure to introduce our next presenting company, Moderna. With us today, we have Lavina Talukdar, SVP, Head of Investor Relations. Questio ...

Moderna, Inc. (NASDAQ:MRNA) Barclays 26th Annual Global Healthcare Conference Call March 12, 2024 2:35 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head, Investor Relations Conference Call Participants Gena Wang - Barclays Gena Wang Welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover SMID cap biotech. It is my great pleasure to introduce our next presenting company, Moderna. With us today, we have Lavina Talukdar, SVP, Head of Investor Relations. Questio ...

Shares of Moderna (MRNA) rose 8.7% on Mar 11, after a government website posted details of the initiation of a phase II/III study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in patients with cutaneous squamous cell carcinoma (CSCC), a form of skin cancer. The therapy is being developed in collaboration with Merck (MRK) .The phase II/III study (called INTerpath-007) will evaluate the safety and efficacy of mRNA-4157, combined with Merck’s blockbuster immuno-oncology drug K ...

Moderna (MRNA) shares soared 8.7% in the last trading session to close at $111.98. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.9% gain over the past four weeks.Share price rose after a government website posted details of initiation of a phase II/III study on mRNA-4157/V940, Moderna’s investigational individualized neoantigen therapy (INT), in patients with cutaneous squamous cell carcinoma (CSCC), a form of skin cancer. T ...

Key TakeawaysThe S&P 500 slipped 0.1% on Monday, March 11, 2024, ahead of inflation data that could affect rate-cut expectations.Shares of EQT fell after the natural gas producer announced plans to purchase pipeline provider Equitrans Midstream.Moderna shares gained amid reports that it will launch a study of its experimental cancer vaccine to treat patients with a form of skin cancer. Major U.S. equities indexes were mixed to open the trading week as stocks fluttered ahead of Tuesday's Consumer Price Infla ...

As an investor, you never really know how your investments will play out. Some companies that have been in long-term decline can suddenly become turnaround stocks and rise again, surprising everyone. While most companies that are undertaking a turnaround strategy fail, some manage to get their act together and regain their competitive edge. This isn’t easy and usually takes a long time to accomplish, but it can be done. And when it happens, shareholders are rewarded with big gains. In the just-completed ear ...

Moderna, Inc. (NASDAQ:MRNA) TD Cowen 44th Annual Health Care Conference March 6, 2024 1:30 PM ET Company Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good afternoon, everyone. Thanks for being here. Welcome again to TD Cowen's 44th Annual Healthcare Conference. My name is Tyler Van Buren, Senior Biotech Analyst here. For this session, it's a privilege to have a fireside chat with Moderna. And from Moderna, it's my pleasure to introduce Stephen ...

The past four years have been a roller-coaster ride for Moderna (MRNA 3.06%). The mRNA-focused vaccine maker rose to prominence following a successful attempt at developing a coronavirus vaccine.However, the stock fell out of favor once sales of the company's only product on the market started moving in the wrong direction. Moderna's shares are down by 30% in the past year, but their total return over the past four years is 230%, and there remain good reasons to invest in the company. 1. Gaining market shar ...

Regarding Moderna (MRNA 2.32%) stock, RBC Capital analyst Luca Issi is bullish. Per his price target of $125 that he reiterated on Feb. 23, the biotech's shares could rise by 30% to reach $125. There are a few upcoming developments that could stimulate the stock to grow in the way that Issi predicts.Management expects its respiratory syncytial virus (RSV) vaccine will pick up a few regulatory approvals in the first half of the year, paving the way for worldwide launches, with sales revenue to follow. Separa ...

Moderna, Inc. (MRNA) reported earnings of 55 cents per share in the fourth quarter of 2023, beating the Zacks Consensus Estimate of a loss of 78 cents. Earnings declined 85% in the quarter. The year-over-year decline in the bottom line was due to lower product sales during the quarter.Revenues in the quarter were $2.81 billion, beating the Zacks Consensus Estimate of $2.55 billion. Total revenues declined 45% year over year due to lower COVID-19 vaccine sales during the quarter.Moderna’s shares were up 6.1% ...